【Denosumab】 RANKL inhibitors Pharmacology Prolia® and Xgeva® Mechanism of Action Simply Explained

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=DF6r3FIkls0

Discover how Denosumab works in this concise 2:19 video! Learn about the crucial roles of osteoclasts and osteoblasts, and how the RANK-RANKL pathway affects bone resorption. Understand the difference of indication between Prolia® and Xgeva®, two powerful medications used to combat osteoporosis and other bone-related conditions. See how Denosumab inhibits osteoclast activation, promoting stronger, healthier bones. Perfect for anyone looking to grasp the essentials of this innovative treatment quickly! • #targetedtherapy #osteoporosis #pharmacology • 【Study Break Oasis】 • 5-Min Forest Oasis: Healing Sounds for Study Stress • • 5-Min Forest Oasis: Healing Sounds fo... • 5-Min Seaside Serenity: Waves of Calmness for Study Stress • • 5-Min Seaside Serenity: Waves of Calm... • 【Notes】 • ▹This video was created based on data as of January 2024, with the purpose of supporting medical students in their exam preparations. • ▹It is not a substitute for medical advice. • ▹Please note that thanks to the tireless efforts of researchers worldwide, this data is updated daily. ▹Unauthorized reproduction is prohibited. • 【Contents】 • 0:00 Denosumab? • 0:06 Basics: osteoblasts and osteoclasts • 0:34 PTH→osteoblast→RANK-L→RANK/osteoclast→bone resorption • 0:53 osteoporosis and Denosumab? • 1:08 Denosumab? • 1:51 Adverse Effects? • 【Reference and figure】 I express my gratitude and respect for your wonderful achievements. • 1. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012 Dec;66(12):1139-46. doi: 10.1111/ijcp.12022. Epub 2012 Sep 12. PMID: 22967310; PMCID: PMC3549483. • 2. Park JH, Lee NK, Lee SY. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Mol Cells. 2017 Oct;40(10):706-713. doi: 10.14348/molcells.2017.0225. Epub 2017 Oct 17. PMID: 29047262; PMCID: PMC5682248. • 3. Lilian I. Plotkin, Nicoletta Bivi, Chapter 3 - Local Regulation of Bone Cell Function, • Editor(s): David B. Burr, Matthew R. Allen, Basic and Applied Bone Biology, Academic Press, 2014,Pages 47-73, ISBN 9780124160156, • https://doi.org/10.1016/B978-0-12-416.... • (https://www.sciencedirect.com/science...) • 4. DRAGBANK online, “Denosumab”, DB06643. • https://go.drugbank.com/drugs/DB06643 • 5. FDA Approved Drug Products: Prolia® (denosumab) Injection, for subcutaneous use (Jan 2024) • https://www.accessdata.fda.gov/drugsa... • 6. FDA Approved Drug Products: Xgeva (denosumab) injection, for subcutaneous use • https://www.accessdata.fda.gov/drugsa... • 7. Yasuyuki Omichi, Shunichi Toki, Toshihiko Nishisho, Takeshi Harada, Nori Sato, Koichi Sairyo, • Atypical femoral fracture in a multiple myeloma patient undergoing treatment with denosumab: A case report and literature review, International Journal of Surgery Case Reports, Volume 108, 2023, 108456, ISSN 2210-2612, • https://doi.org/10.1016/j.ijscr.2023..... • (https://www.sciencedirect.com/science...) • 8. Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, Sutton D, Grimer R, Högler W. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. J Clin Endocrinol Metab. 2018 Feb 1;103(2):596-603. doi: 10.1210/jc.2017-02025. PMID: 29211870.

#############################

New on site